Published in final edited form as:

Curr Opin Infect Dis. 2011 February ; 24(1): 56–61. doi:10.1097/QCO.0b013e3283421081.

Immunity and vaccines against sexually transmitted *Chlamydia trachomatis* infection

Sarah E. M. Howie¹, Patrick J. Horner², Andrew W. Horne³, and Gary Entrican⁴

¹MRC/University of Edinburgh Centre for Inflammation Research

²School of Social and Community Medicine, University of Bristol.

³Centre for Reproductive Biology, University of Edinburgh

⁴Moredun Research Institute and the Roslin Institute, Royal (Dick) School of Veterinary Studies, University of Edinburgh

Abstract

Purpose of review—To review recent findings on immunity and vaccine development to *Chlamydia trachomatis*.

Recent findings—There is increasing knowledge on the interactions between *Chlamydia trachomatis* and infected host cells. During genital infection the organism avoids generating protective immunity but immune responses to a number of chlamydial proteins have been associated with reproductive tract pathology. Various vaccine and adjuvant preparations have been tried experimentally. Information generated by proteomics and complex studies of serological and T-lymphocyte immune responses points to novel vaccine candidates.

Summary—*Chlamydia trachomatis*, an obligate intracellular bacterium, is the commonest sexually transmitted infection worldwide and is associated with reproductive pathology. To develop rational vaccines it is necessary to understand the complex life-cycle of the organism, the host immune response to infection and how these relate to disease. Infection does not prevent reinfection and antibiotic treatment prevents antibody production at a population level. It remains unclear what type of immune response would be sufficient to prevent infection and/or reinfection. Although the prevalence and demographics of infection and the severity of disease associations suggest it would be desirable, there is no vaccine currently available. A number of studies have identified novel vaccine candidates.

Keywords

Chlamydia trachomatis; Immunity; Vaccination

The clinical problem - *Chlamydia trachomatis* and reproductive tract disease

Chlamydia trachomatis (Ct) is a gram-negative, obligate intracellular bacterium. Serovars A-C cause trachoma, D-K cause the common sexually transmitted infection (STI), L1-L2 cause lymphogranuloma venereum (LGV)[1]. This review focuses on immunity and vaccination against the common STI.

Prevalence of Ct STI in Europe is 1- 3% of the population between the ages of 18-44. Re-infection is common and most cases are asymptomatic[2]. It is accepted that Ct STI in some women leads to pelvic inflammatory disease (PID), tubal infertility and ectopic pregnancy although the evidence remains associative. There is also pathology associated with genital infection in men[3;4].

The host response to infection - Immunity and disease following *Chlamydia trachomatis* STI

Since widespread antibiotic therapy was introduced serum anti-Ct antibodies have declined in parallel with increased Ct prevalence[5**;6]. Whilst clearing infection, antibiotics may alter the development of immunity. It remains controversial whether pathology is caused directly by infection or by the immune response. There is evidence that women who make a pro-inflammatory, interferon- γ (IFN- γ) dominated cytokine response (T helper Type 1/ Th1 response) have less re-infection and infertility than those who make IL-10 and IL-4 dominated Th2 responses[7*;8*]. As IFN- γ induces a persistent non-infectious state in Ct in vitro[9*;10] it remains unclear whether a Th1 response completely clears infection in vivo. Th1 dependent IgG2 antibodies to Ct antigens are higher in women with cervicitis and PID[11*] indicating that Th1 responses may be associated with inflammatory pathology.

The potential solution - Is a vaccine likely to be beneficial?

Modelling indicates that fully protective vaccination would eliminate Ct epidemics in 20 years. A partially effective vaccine would reduce disease in men and women, but cost-benefit would be greater for vaccinating women only[12*]. To develop vaccines it is necessary to understand how Ct gains entry to and survives inside host cells; which bacterial proteins induce immune responses; and, which immune responses are protective.

Protective immunity generated by vaccination should not be confused with the immune response to STI. This is due to the context in which Ct antigens are seen by the immune system. In vaccination this is determined by the adjuvant(s) used and the route of administration. In natural infection Ct has evolved mechanisms to ensure that immune responses are suboptimal and/or are directed at proteins which are not essential for transmission or reinfection.

Complexity in miniature – the *Chlamydia trachomatis* lifecycle

The Ct chromosome encodes nearly 1000 proteins. Most isolates have a plasmid encoding 8 or 9 proteins which influence bacterial gene transcription[13*]. Ct has a bi-morphic life-cycle. The metabolically inactive, infectious, elementary bodies (EBs) have an extensively cross-linked outer membrane which makes them very stable extracellularly. The main structural components are the major outer membrane protein (MOMP/OmpA), OmcA and OmcB. Other proteins are involved in tropism and attachment. Heinz et al [14*] used an in silico approach and Liu et al[15*] used proteomics to identify several outer membrane proteins which may be targets for intervention strategies.

Inside permissive cells, EBs transition into rapidly dividing reticulate bodies (RBs) within host membrane bound inclusion bodies. Midway through the 48-72hr replication cycle some RBs transition to infectious EBs. The inclusion body expands and EBs are released by cell lysis or by extrusion of inclusion bodies. In vitro, persistent infection (blocking of RB to EB transition and generation of aberrant RB forms) results from exposure to penicillin, IFN- γ , HSV infection and nutrient deprivation[9*;10]. Skilton et al[16**] demonstrated that penicillin removal from persistently infected cultures causes aberrant RBs to bud and form

normal RBs which then complete replication. Whether persistent infection occurs in vivo remains uncertain[9*;16**].

Manipulating the environment - Pathogen induced host cell changes

Ct can use the cystic fibrosis transmembrane conductance regulator (CFTR) membrane protein to enter cells[17*]. CFTR upregulation is associated with Ct induced female infertility[18*]. EB entry depends on host membrane protein disulfide isomerase (PDI) [19*] which targets cross-linked EB outer membrane proteins. PDI is a component of the estrogen receptor alpha (ERalpha) complex which associates with Ct attached to human endometrial epithelial cells[20]. Interaction with the ERalpha complex may be a target for prevention of infection as the co-receptor protein SRAP-1 is targeted by a Ct protease (CT441) to inhibit ERalpha signalling[21*].

Inside host cells Ct circumvents endogenous stress mechanisms, prevents lysosomal fusion, inhibits apoptosis, and evades intracellular innate immunity. Cocchiaro and Valdivia[22*] reviewed intracellular survival mechanisms and Betts et al[23*] reviewed how Ct effector proteins alter host cells. On entry, the EB protein TARP translocates into the cytoplasm, is phosphorylated by Src and remodels actin to allow the EB to move within the cell. The EB becomes surrounded by host cell membrane to form the inclusion body and Ct proteins are inserted into the inclusion body membrane. The inclusion body diverts and fuses with host cell vesicles containing nutrients necessary for replication. CPAF, a RB protease secreted into the cytoplasm, degrades cytoskeletal elements to allow inclusion body expansion and release of EBs; and processes intermediate-filament proteins to stabilize the inclusion bodies and minimize exposure to intracellular innate immune mechanisms[24*]. CPAF also degrades pro-apoptotic proteins[24*] and TARP interacts with the host adaptor protein SHC1 to inhibit apoptosis[25*]. Caspase-1 activation promotes Ct replication[26*]. Ct disrupts several signalling pathways[27*]. In epithelial cells RAS decouples from MAPK/ERK (MEK) signalling although the effects differ in human and murine cells[28**]. The Ct proteins ChlaDub1 and CT441 interfere with host cell NF- κ B signalling[23*].

Fighting back - Immune responses to *Chlamydia trachomatis*

Each Ct protein may possess multiple antigenic epitopes that could be recognized by the acquired immune system. Some Ct molecules (proteins, LPS, lipids and CpG-oligonucleotides) have pathogen associated molecular patterns (PAMPS) which can be recognized by innate immune system receptors (PRRs).

Avoiding innate immunity

Ct EBs have evolved to avoid innate immunity in the reproductive tract. Innate immune mechanisms include those triggered by membrane bound host PRRs, such as the Toll-like receptors (TLRs)[29] and NOD-1[30] which depend on NF- κ B signalling. Although Ct LPS and proteins activate PRRs in vitro, responses to live infection are more muted suggesting that disruption of NF- κ B signalling inhibits innate responses[31*]. NF- κ B was degraded in Ct infected human trophoblast cells [32*].

Fallopian tubes from Ct infected women with ectopic pregnancy have increased inducible nitric oxide synthase/iNOS and increased pro-inflammatory molecules, activins, which are involved in scarring[33*]. Thus inflammation may kill bacteria but chronic inflammation can cause tissue damage and this may partly explain why this study, like others, failed to detect Ct in diseased Fallopian tubes.

Immunological markers of infection, pathology and protective immunity

Antibodies and T-lymphocyte responses to several Ct proteins have been described. Infection rate and organism load on reinfection decrease with age suggesting development of at least partial protective immunity[34].

Antibody responses require CD4-T-lymphocyte 'help'. B-lymphocytes and antibodies recognize 'native-protein' epitopes which are not necessarily linear, whereas T-lymphocytes recognise short linear peptides in the context of self MHC-I for CD8-T-cells and self MHC-II for CD4-T-cells. CD4-T-cells can be activated as pro-inflammatory Th17 and Th1 cells or as Th2 cells. Both Th1 and Th2 cells help B-cells to make antibody but the immunoglobulin subclasses produced differ. As different immunoglobulin subclasses vary in biological activity this may be relevant to pathology following infection.

A major antigenic source is the inclusion body. Ct encodes 50 inclusion body (Inc) proteins, 22 of which are in inclusion membranes[35*]. Antibodies to Inc proteins are found in sera from infected women[11*;35*], and both CD4-[36*] and CD8-[37*] T-cells respond to Inc epitopes. Not all Ct proteins generate antibodies in every individual. Commercially available tests detect anti-EB antibodies by immunofluorescence or anti-MOMP antibodies by ELISA. Anti-EB antibodies were correlated with Fallopian tube damage in sub-fertile women[38]. ELISA assays suggest that Ct795[39*], and the plasmid encoded Pgp3[40*] may be good serological markers of infection. Infected women have IgG antibodies to MOMP, IncB and IncC and IgG2 (a Th1 dependent subclass) is the prevalent subclass of anti-Inc antibodies[11*]. Antibody titres to IncB and IncC correlate with cervicitis and PID being highest in cervicitis[11*]. CD4-T-cell responses to IncB and IncC in infertile women generated a Th2 cytokine pattern whilst fertile women showed a Th1 pattern[8*].

Ct heat shock proteins (cHSPs) are analogous to human HSPs and antibodies to cHSP60 are associated with autoimmunity[41*]. Ct STI is associated with antibodies to sperm in semen and IgG antibodies to cHSP60 are associated with reproductive failure. Sperm have several surface HSPs and cross-reaction with cHSPs may initiate autoimmune responses to sperm[42*]. IgG responses to cHSP60 does not correlate with pathology in women[43*] but women with tubal infertility have a high prevalence of antibodies to cHSP60[44*].

Rank and Whitum-Hudson[45*] reviewed experimental evidence for protective acquired immunity. In guinea-pigs antibody protects against reinfection and serum IgG is more important than local IgA. In mice both Th1 cells and antibody contribute directly to protection. MOMP is immunodominant, but MOMP immunization only protects if the protein is non-reduced, emphasizing the importance of native-protein B cell epitopes. Antibiotic therapy clears experimental infection but prevents generation of immunity[45*].

Vaccination

Important considerations for vaccination include: who to vaccinate; which antigen(s) to use; which administration route to use; and, which adjuvant to use.

There are two stages in the Ct lifecycle which a prophylactic vaccine should 'hit': 1) cell-adhesion, for which antibody would be most useful and 2) early-mid replication where T-cells might be targeted against bacterial antigens in infected cell membranes. Both responses would require CD4-T-cell activation. Acquired immunity is polarized by the antigen presenting cells (usually local dendritic cells/DCs) which first activate CD4-T-cell responses. Thus adjuvant activation of DCs local to the vaccination site is crucial. It should be remembered that although animal studies establish general principles, the fine details of immunity differ between species, and, although Ct is closely related to the widely used

murine pathogen *C. muridarum* (which is, somewhat confusingly, also referred to as the mouse pneumonitis strain of *C. trachomatis*) their biology is not identical.

A strong IFN- γ response of lymphocytes to Ct antigen correlates with resistance to infection among sex workers[46*]. An immunoproteomic analysis of *C. muridarum* indicates the two most likely vaccine candidates were PmpG and PmpE/F which several mouse strains recognise. However, peptides of these proteins used to vaccinate one mouse strain are not recognized by others arguing for whole protein rather than peptide vaccination. CpG oligonucleotide adjuvant does not induce protection perhaps due to lack of Th17 induction[46*]. The balance between Th1/Th17 responses explains different susceptibilities of mouse strains to *C. muridarum*[47*]. MOMP administered in Lipid-C adjuvant both transcutaneously[48*] and orally[49*] induces protection against vaginal *C. muridarum* which is enhanced via the oral route when CpG oligonucleotides and cholera toxin are incorporated into the Lipid-C[49*]. CT043, a conserved Inc protein, is a CD4-T-cell target and may be a vaccine candidate[50*]. Ct ArtJ [a protein conserved among chlamydial species] may also be a vaccine candidate with the additional benefit of also generating protection against the related human lung pathogen *C. pneumoniae*[51**]. CPAF induces protection against vaginal *C. muridarum* which is boosted with IL-12 or CpG oligonucleotides as adjuvant[52*]. Live infection induces Th1 responses whilst immunization with inactivated organisms induces Th2 responses[53*]. TARP is an immunodominant protein and protects mice against *C. muridarum* infection[54*].

The human Ct “antigen-ome” in sera from 99 infected women is very broad as over 700 Ct proteins were recognized by more than one serum[55**]. Mice given either live CT infection or immunized with dead organisms were used to identify infection dependent and independent antigens which were tested against sera from infected women. The most recognized infection dependent protein (by 94% of sera) is CPAF. The most recognized infection independent protein (by 96% of sera) is Pgp3[55**]. Use of serologically recognized proteins to identify CD4-T-cell epitopes also identified CPAF as a widely recognized serological antigen although in this series CT875 was the most commonly recognized protein[56**]. MOMP is the most widely recognised T-cell epitope but CT875 stimulates most combined T-cell and serum responses[56**].

Concluding remarks

Understanding the natural history of infection, the host immune response and how these impact on subsequent pathology is crucial to rational vaccine design. Prophylactic vaccination aims to protect before infection. Therapeutic vaccination aims to boost or alter the immune response generated in previously infected individuals. There can be no doubt that vaccines against Ct would be of benefit to health and are likely to have a significant impact on healthcare costs. More work on identifying and testing vaccine candidates and appropriate delivery systems is needed.

Acknowledgments

GE is funded by the Scottish Government Rural and Environmental Research and Analysis Directorate (RERAD). AH is supported by an MRC Clinician Scientist Fellowship.

Abbreviations

CFTR	cystic fibrosis transmembrane conductance regulator protein
ChlaDub1	Chlamydial Deubiquitinase and deneddylase Dub1

CPAF	chlamydial protease/proteasome-like activity factor
Ct	<i>Chlamydia trachomatis</i>
DC	dendritic cell
EB	elementary body
ELISA	enzyme linked immunosorbent assay
ERalpha	estrogen receptor alpha
HSP	heat shock protein
HSV	herpes simplex virus
IFN-γ	interferon- γ
IgG2	Immunoglobulin subclass G2
LGV	lymphogranuloma venereum
IL	interleukin
iNOS	inducible nitric oxide synthase
LPS	lipopolysaccharide
MAPK /ERK	mitogen activated protein kinase
MHC	Major Histocompatibility Complex (protein)
MOMP	major outer membrane protein
NF-κB	nuclear factor kappa-B
NOD-1	nucleotide-binding oligomerization domain containing 1
PAMP	pathogen associated molecular pattern
PDI	protein disulfide isomerase
PID	pelvic inflammatory disease
PRR	pattern recognition receptor
RAS	RAt sarcoma GTPase
RB	reticulate body
SRAP-1	Steroid receptor RNA activator 1
STI	sexually transmitted infection
TARP	translocated actin recruiting phosphoprotein
Th	T helper lymphocyte
TLR	Toll-like receptor

Reference List

1. Thomson NR, Holden MT, Carder C, et al. Chlamydia trachomatis: genome sequence analysis of lymphogranuloma venereum isolates. *Genome Res.* 2008; 18:161–71. [PubMed: 18032721]
2. Carey AJ, Beagley KW. Chlamydia trachomatis, a hidden epidemic: effects on female reproduction and options for treatment. *Am.J.Reprod.Immunol.* 2010; 63:576–86. [PubMed: 20192953]
3. Cunningham KA, Beagley KW. Male genital tract chlamydial infection: implications for pathology and infertility. *Biol.Reprod.* 2008; 79:180–9. [PubMed: 18480466]

4. Ouzounova-Raykova V, Ouzounova I, Mitov I. Chlamydia trachomatis infection as a problem among male partners of infertile couples. *Andrologia*. 2009; 41:14–19. [PubMed: 19143724]
- **5. Lyytikäinen E, Kaasila M, Hiltunen-Back E, et al. A discrepancy of Chlamydia trachomatis incidence and prevalence trends in Finland 1983-2003. *BMC.Infect.Dis.* 2008; 8:169. [PubMed: 19094207] [Population based study of women in Finland where banked serum indicated decline in Ct seroprevalence between 1983-2003 whereas incidence of infection increased.]
6. Lyytikäinen E, Kaasila M, Koskela P, et al. Chlamydia trachomatis seroprevalence atlas of Finland 1983-2003. *Sex Transm.Infect.* 2008; 84:19–22. [PubMed: 17911135]
- *7. Agrawal T, Gupta R, Dutta R, et al. Protective or pathogenic immune response to genital chlamydial infection in women--a possible role of cytokine secretion profile of cervical mucosal cells. *Clin.Immunol.* 2009; 130:347–54. [PubMed: 19019735] [Experimental evidence on cervical mucosal cell cytokine response from Ct infected women indicating a Th1 response in fertile and a Th2 response in infertile women.]
- *8. Gupta R, Vardhan H, Srivastava P, Salhan S, Mittal A. Modulation of cytokines and transcription factors (T-Bet and GATA3) in CD4 enriched cervical cells of Chlamydia trachomatis infected fertile and infertile women upon stimulation with chlamydial inclusion membrane proteins B and C. *Reprod.Biol.Endocrinol.* 2009; 7:84. [PubMed: 19698128] [Shows that cervical Th1 cells from fertile women, and Th2 cells from infertile women, recognize epitopes in chlamydial inclusion body proteins.]
- *9. Wyrick PB. Chlamydia trachomatis persistence in vitro: an overview. *J.Infect.Dis.* 2010; 201(Suppl 2):S88–S95. [PubMed: 20470046] [Good review of the induction of in vitro persistent infection.]
10. Huston WM, Theodoropoulos C, Mathews SA, Timms P. Chlamydia trachomatis responds to heat shock, penicillin induced persistence, and IFN-gamma persistence by altering levels of the extracytoplasmic stress response protease HtrA. *BMC.Microbiol.* 2008; 8:190. [PubMed: 18986550]
- *11. Gupta R, Salhan S, Mittal A. Seroprevalence of antibodies against Chlamydia trachomatis inclusion membrane proteins B and C in infected symptomatic women. *J.Infect.Dev.Ctries.* 2009; 3:191–8. [PubMed: 19759474] [Experimental evidence that antibodies to Inc proteins are immunodominant in infected women and that Th1 dependent IgG2 antibodies may be associated with cervicitis and PID.]
- *12. Gray RT, Beagley KW, Timms P, Wilson DP. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. *J.Infect.Dis.* 2009; 199:1680–8. [PubMed: 19432550] [Mathematical model of cost benefits of Ct vaccines.]
- *13. Carlson JH, Whitmire WM, Crane DD, et al. The Chlamydia trachomatis plasmid is a transcriptional regulator of chromosomal genes and a virulence factor. *Infect.Immun.* 2008; 76:2273–83. [PubMed: 18347045] [Characterisation of Ct plasmid gene functions.]
- *14. Heinz E, Tischler P, Rattei T, Myers G, Wagner M, Horn M. Comprehensive in silico prediction and analysis of chlamydial outer membrane proteins reflects evolution and life style of the Chlamydiae. *BMC.Genomics.* 2009; 10:634. [PubMed: 20040079] [Annotation of Ct EB outer membrane proteins with a link to the database of results.]
- *15. Liu X, Afrane M, Clemmer DE, Zhong G, Nelson DE. Identification of Chlamydia trachomatis outer membrane complex proteins by differential proteomics. *J.Bacteriol.* 2010; 192:2852–60. [PubMed: 20348250] [Further identification of proteins in CT EB outer membrane complex.]
- **16. Skilton RJ, Cutcliffe LT, Barlow D, et al. Penicillin induced persistence in Chlamydia trachomatis: high quality time lapse video analysis of the developmental cycle. *PLoS One.* 2009; 4:e7723. [PubMed: 19893744] [Fantastic videos of Ct infection cycle and persistent infection.]
- *17. Ajonuma LC, Fok KL, Ho LS, et al. CFTR is required for cellular entry and internalization of Chlamydia trachomatis. *Cell Biol.Int.* 2010; 34:593–600. [PubMed: 20178459] [First description of CFTR as a chlamydial receptor.]
- *18. He Q, Tsang LL, Ajonuma LC, Chan HC. Abnormally up-regulated cystic fibrosis transmembrane conductance regulator expression and uterine fluid accumulation contribute to Chlamydia trachomatis-induced female infertility. *Fertil.Steril.* 2010; 93:2608–14. [PubMed: 20227074] [First description of CFTR involvement in Ct related female infertility.]

- *19. Abromaitis S, Stephens RS. Attachment and entry of Chlamydia have distinct requirements for host protein disulfide isomerase. *PLoS Pathog.* 2009; 5:e1000357. [PubMed: 19343202] [Evidence that enzymatic activity of PDI is necessary for Ct entry into cells.]
- 20. Davis CH, Raulston JE, Wyrick PB. Protein disulfide isomerase, a component of the estrogen receptor complex, is associated with Chlamydia trachomatis serovar E attached to human endometrial epithelial cells. *Infect.Immun.* 2002; 70:3413–8. [PubMed: 12065480]
- *21. Borth N, Massier J, Franke C, Sachse K, Saluz HP, Hanel F. Chlamydial protease CT441 interacts with SRAP1 co-activator of estrogen receptor alpha and partially alleviates its co-activation activity. *J.Steroid Biochem.Mol.Biol.* 2010; 119:89–95. [PubMed: 20079837] [First description that Ct protease inhibits ERalpha activity.]
- *22. Cocchiari JL, Valdivia RH. New insights into Chlamydia intracellular survival mechanisms. *Cell Microbiol.* 2009; 11:1571–8. [PubMed: 19673891] [Review of Ct lifecycle and host cell interactions.]
- *23. Betts HJ, Wolf K, Fields KA. Effector protein modulation of host cells: examples in the Chlamydia spp. arsenal. *Curr.Opin.Microbiol.* 2009; 12:81–7. [PubMed: 19138553] [Review of Ct effector protein interactions with host cell pathways.]
- *24. Murthy AK, Guentzel MN, Zhong G, Arulanandam BP. Chlamydial protease-like activity factor--insights into immunity and vaccine development. *J.Reprod.Immunol.* 2009; 83:179–84. [PubMed: 19853923] [Review of Ct CPAF as vaccine candidate.]
- *25. Mehlitz A, Banhart S, Maurer AP, et al. Tarp regulates early Chlamydia-induced host cell survival through interactions with the human adaptor protein SHC1. *J.Cell Biol.* 2010; 190:143–57. [PubMed: 20624904] [Experimental and bio-informatic analysis of the role of Ct TARP in preventing apoptosis of infected cells.]
- *26. Abdul-Sater AA, Koo E, Hacker G, Ojcius DM. Inflammasome-dependent caspase-1 activation in cervical epithelial cells stimulates growth of the intracellular pathogen Chlamydia trachomatis. *J.Biol.Chem.* 2009; 284:26789–96. [PubMed: 19648107] [First description that host cell caspase-1 activation promotes Ct growth.]
- *27. Zhong G. Killing me softly: chlamydial use of proteolysis for evading host defenses. *Trends Microbiol.* 2009; 17:467–74. [PubMed: 19765998] [Review of Ct proteolysis induced disruption of host cell protein functions.]
- **28. Vignola MJ, Kashatus DF, Taylor GA, Counter CM, Valdivia RH. cPLA2 regulates the expression of type I interferons and intracellular immunity to Chlamydia trachomatis. *J.Biol.Chem.* 2010; 285:21625–35. [PubMed: 20452986] [Experimental evidence of host cell signaling disruption to evade innate immunity.]
- 29. McGettrick AF, O'Neill LA. Localisation and trafficking of Toll-like receptors: an important mode of regulation. *Curr.Opin.Immunol.* 2010; 22:20–7. [PubMed: 20060278]
- 30. Shaw MH, Reimer T, Kim YG, Nunez G. NOD-like receptors (NLRs): bona fide intracellular microbial sensors. *Curr.Opin.Immunol.* 2008; 20:377–82. [PubMed: 18585455]
- *31. Joyee AG, Yang X. Role of toll-like receptors in immune responses to chlamydial infections. *Curr.Pharm.Des.* 2008; 14:593–600. [PubMed: 18336303] [Ct infection is less active than isolated PAMPs in TLR signaling.]
- *32. de la Torre E, Mulla MJ, Yu AG, Lee SJ, Kavathas PB, Abrahams VM. Chlamydia trachomatis infection modulates trophoblast cytokine/chemokine production. *J.Immunol.* 2009; 182:3735–45. [PubMed: 19265152] [Ct cleaves NFκB and disrupts cytokine production in infected cells.]
- *33. Refaat B, Al-Azemi M, Geary I, Eley A, Ledger W. Role of activins and inducible nitric oxide in the pathogenesis of ectopic pregnancy in patients with or without Chlamydia trachomatis infection. *Clin.Vaccine Immunol.* 2009; 16:1493–503. [PubMed: 19692623] [Describes iNOS and activins upregulation in Fallopian tubes of Ct infected women with ectopic pregnancy.]
- 34. Batteiger BE, Xu F, Johnson RE, Rekart ML. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. *J.Infect.Dis.* 2010; 201(Suppl 2):S178–S189. [PubMed: 20524235]
- *35. Li Z, Chen C, Chen D, Wu Y, Zhong Y, Zhong G. Characterization of fifty putative inclusion membrane proteins encoded in the Chlamydia trachomatis genome. *Infect.Immun.* 2008;

- 76:2746–57. [PubMed: 18391011] [Description of Ct inclusion membrane proteins and their recognition by sera from infected women.]
- *36. Gupta R, Srivastava P, Vardhan H, Salhan S, Mittal A. Host immune responses to chlamydial inclusion membrane proteins B and C in *Chlamydia trachomatis* infected women with or without fertility disorders. *Reprod.Biol.Endocrinol.* 2009; 7:38. [PubMed: 19397832] [CD4-T-lymphocytes recognize Ct Inc protein epitopes.]
 - *37. Fling SP, Sutherland RA, Steele LN, et al. CD8+ T cells recognize an inclusion membrane-associated protein from the vacuolar pathogen *Chlamydia trachomatis*. *Proc. Natl. Acad. Sci. U.S.A.* 2001; 98:1160–5. [PubMed: 11158611] [CD8-T-lymphocytes recognize Ct Inc protein epitopes.]
 - 38. El Hakim EA, Gordon UD, Akande VA. The relationship between serum *Chlamydia* antibody levels and severity of disease in infertile women with tubal damage. *Arch.Gynecol.Obstet.* 2010; 281:727–33. [PubMed: 19760187]
 - *39. Frikha-Gargouri O, Gdoura R, Znazen A, Gargouri J, Hammami A. Diagnostic value of enzyme-linked immunosorbent assays using hypothetical proteins CT226 and CT795 as antigens in *Chlamydia trachomatis* serodiagnosis. *Diagn.Microbiol.Infect.Dis.* 2009; 65:224–31. [PubMed: 19766431] [ELISA against CT795 is a sensitive method for detecting antibodies in Ct infected patients.]
 - *40. Wills GS, Horner PJ, Reynolds R, et al. Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of *Chlamydia trachomatis* infection. *Clin.Vaccine Immunol.* 2009; 16:835–43. [PubMed: 19357314] [Comparison of a number of different ELISAs indicates that anti-PgP3 serum antibody detection is the most sensitive.]
 - *41. Campanella C, Gammazza A Marino, Mularoni L, Cappello F, Zummo G, Di F.V. A comparative analysis of the products of GROEL-1 gene from *Chlamydia trachomatis* serovar D and the HSP60 var1 transcript from *Homo sapiens* suggests a possible autoimmune response. *Int.J.Immunogenet.* 2009; 36:73–8. [PubMed: 19207939] [Evidence that CHSP60 similarity to host HSPs may induce autoimmune reactions.]
 - *42. Naaby-Hansen S, Herr JC. Heat shock proteins on the human sperm surface. *J.Reprod.Immunol.* 2010; 84:32–40. [PubMed: 19962198] [Evidence that HSPs are present on the surface of sperm and that some of these share epitopes with host cell HSPs.]
 - *43. Huston WM, Armitage CW, Lawrence A, et al. HtrA, RseP, and Tsp proteins do not elicit a pathology-related serum IgG response during sexually transmitted infection with *Chlamydia trachomatis*. *J.Reprod.Immunol.* 2010; 85:168–71. [PubMed: 20444505] [Antibodies to CHSP60 are common in infected women but not with upper genital tract pathology.]
 - *44. Rodgers AK, Wang J, Zhang Y, et al. Association of tubal factor infertility with elevated antibodies to *Chlamydia trachomatis* caseinolytic protease P. *Am.J.Obstet.Gynecol.* 2010 [High titres of antibodies to CHSP60 in infected women with tubal infertility.]
 - *45. Rank RG, Whittum-Hudson JA. Protective immunity to chlamydial genital infection: evidence from animal studies. *J.Infect.Dis.* 2010; 201(Suppl 2):S168–S177. [PubMed: 20470052] [Review of experimental studies.]
 - *46. Karunakaran KP, Yu H, Foster LJ, Brunham RC. Development of a *Chlamydia trachomatis* T cell vaccine. *Hum.Vaccin.* 2010; 6:1–5. [Review of work using immunoproteomics to identify vaccine candidates to induce Th1 immunity against Ct.]
 - *47. Jiang X, Shen C, Yu H, Karunakaran KP, Brunham RC. Differences in innate immune responses correlate with differences in murine susceptibility to *Chlamydia muridarum* pulmonary infection. *Immunology.* 2010; 129:556–66. [PubMed: 20102413] [Experimental evidence that the balance between Th17 and Th1 responses are involved in susceptibility to chlamydial infection.]
 - *48. Hickey DK, Aldwell FE, Beagley KW. Transcutaneous immunization with a novel lipid-based adjuvant protects against *Chlamydia* genital and respiratory infections. *Vaccine.* 2009; 27:6217–25. [PubMed: 19698810] [Experimental studies showing transcutaneous immunization using lipid adjuvant protects against chlamydial infection.]
 - *49. Hickey DK, Aldwell FE, Beagley KW. Oral immunization with a novel lipid-based adjuvant protects against genital *Chlamydia* infection. *Vaccine.* 2010; 28:1668–72. [PubMed: 20026449] [Experimental studies showing oral immunization using lipid adjuvant protects against

chlamydial infection and the effect is boosted when CpG-oligonucleotides or IL-12 are incorporated into the adjuvant matrix.]

- *50. Meoni E, Faenzi E, Frigimelica E, et al. CT043, a protective antigen that induces a CD4+ Th1 response during Chlamydia trachomatis infection in mice and humans. *Infect.Immun.* 2009; 77:4168–76. [PubMed: 19596772] [Experimental and human serological studies indicating that a Ct Inc protein may be a good vaccine candidate.]
- **51. Soriani M, Petit P, Grifantini R, et al. Exploiting antigenic diversity for vaccine design: the Chlamydia ArtJ paradigm. *J.Biol.Chem.* 2010 M110.118513 Epub ahead of print. [Functional and structural studies indicating ArtJ may be a good vaccine candidate to protect against both CT and *C. pneumoniae*.]
- *52. Chaganty BK, Murthy AK, Evani SJ, et al. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. *Vaccine.* 2010; 28:2323–9. [PubMed: 20056182] [Denatured Ct CPAF can vaccinate against *C muridarum*.]
- *53. Molina DM, Pal S, Kayala MA, et al. Identification of immunodominant antigens of Chlamydia trachomatis using proteome microarrays. *Vaccine.* 2010; 28:3014–24. [PubMed: 20044059] [*C. muridarum* infection induced Th1 responses, immunization with inactivated organisms proteins induced Th2 responses. Proteomics were used to identify immunodominant antigens.]
- *54. Wang J, Chen L, Chen F, et al. A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice. *Vaccine.* 2009; 27:2967–80. [PubMed: 19428908] [TARP identified as an immunodominant Ct antigen in humans and Th1 anti-TARP responses in mice protected against *C. muridarum* infection.]
- **55. Wang J, Zhang Y, Lu C, Lei L, Yu P, Zhong G. A Genome-Wide Profiling of the Humoral Immune Response to Chlamydia trachomatis Infection Reveals Vaccine Candidate Antigens Expressed in Humans. *J.Immunol.* 2010; 185:1670–80. [PubMed: 20581152] [Translational and experimental approaches used human sera from Ct infected women to identify immunodominant antigens. Mice were infected or immunized with inactivated organisms and infection dependent and independent antigens within the immunodominant set identified.]
- **56. Coler RN, Bhatia A, Maisonneuve JF, et al. Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis. *FEMS Immunol.Med.Microbiol.* 2009; 55:258–70. [PubMed: 19281568] [Translational and experimental approaches used human T cells to identify candidate vaccine antigens and test these in experimental infection.]

Key Points

- *Chlamydia trachomatis* genital infection is associated with subsequent reproductive pathology and infertility
- Infection with *Chlamydia trachomatis* induces partial immunity at best
- Vaccination against *Chlamydia trachomatis* would significantly reduce disease burden and health care costs
- Protective immunity can be induced experimentally
- Human *Chlamydia trachomatis* vaccine candidates and adjuvants require further study